December 20, 2023
1 min watch
Save
VIDEO: Avacincaptad pegol for GA shows continued benefit at 24 months
In this video, Esther M. Bowie, MD, discusses the results of the GATHER2 trial, presented at the American Academy of Ophthalmology meeting.
The double-masked phase 3 trial study evaluated the safety and efficacy of avacincaptad pegol, which was approved by the FDA in August. Results showed that after 24 months, patients with geographic atrophy who were treated with avacincaptad pegol experienced continued benefit as compared with patients who received sham injection, according to Bowie, a professor of ophthalmology at Penn State Health Milton S. Hershey Medical Center.
“The effects pretty much doubled in the treatment vs. the sham group, so that was exciting,” she said.
Reference:
- Khanani AM. Gather2: Two-year data. Presented at: American Academy of Ophthalmology meeting; Sept. 30-Oct. 3, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Bowie reports no relevant financial disclosures.